Table 1.
Main characteristics of publications included in this meta-analysis.
| Study | Languages | Type | Country | Sample size | Cancer type | Details of WFO treatment schemes | Outcome measure |
|---|---|---|---|---|---|---|---|
| Choi 201915 | English | Article | Korea | 65 | Gastric cancer | R + C + NR + NA | ① |
| Kim 201916 | English | Article | Korea | 69 | Colorectal cancer | R + C + (NR + NA)a | ①③④ |
| Zhou 201917 | English | Article | China | 362 | Colon, rectal, lung, breast, stomach, cervical and ovarian cancer | R + C + NR + NA | ①② |
| Hu 201818 | Chinese | Article | China | 30 | Colon cancer | R + C + NR + NA | ① |
| Liu 201819 | English | Article | China | 149 | Lung cancer | R + C + NR + NA | ①② |
| Somashekhar 201820 | English | Article | India | 638 | Breast cancer | R + C + NR + NA | ①② |
| Xu 201821 | Chinese | Article | China | 132 | Breast cancer | R + C + NR + NA | ①② |
| Lee 201822 | English | Article | Korea | 656 | Colon cancer | R + (C + NR + NA)a | ①③④ |
| Somashekhar 201723 | English | Conference abstract | India | 362 | Colon, rectal and lung cancer | R + C + NR + NA | ① |
R Recommended, C for consideration, NR not recommended, NA not available.
① Clinical staging, ② Pathological subtypes, ③ ECOG performance status, ④ Age.
aThe data in brackets represent that only the merged data were given, and not each item of data was given separately.